Financial Survey: PAREXEL International (PRXL) & Crispr Therapeutics (CRSP)

PAREXEL International (NASDAQ: PRXL) and Crispr Therapeutics (NASDAQ:CRSP) are both biotechnology & medical research – nec companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.

Earnings and Valuation

This table compares PAREXEL International and Crispr Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PAREXEL International N/A N/A N/A $2.05 42.97
Crispr Therapeutics $5.16 million 168.13 -$23.17 million ($0.32) -66.09

PAREXEL International has higher earnings, but lower revenue than Crispr Therapeutics. Crispr Therapeutics is trading at a lower price-to-earnings ratio than PAREXEL International, indicating that it is currently the more affordable of the two stocks.


This table compares PAREXEL International and Crispr Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PAREXEL International 4.62% 19.95% 5.29%
Crispr Therapeutics -466.58% -38.42% -25.26%

Institutional and Insider Ownership

87.5% of PAREXEL International shares are owned by institutional investors. Comparatively, 24.5% of Crispr Therapeutics shares are owned by institutional investors. 2.9% of PAREXEL International shares are owned by insiders. Comparatively, 40.0% of Crispr Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for PAREXEL International and Crispr Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAREXEL International 1 5 2 0 2.13
Crispr Therapeutics 0 3 3 0 2.50

PAREXEL International currently has a consensus price target of $78.30, indicating a potential downside of 11.10%. Crispr Therapeutics has a consensus price target of $22.38, indicating a potential upside of 5.79%. Given Crispr Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Crispr Therapeutics is more favorable than PAREXEL International.


PAREXEL International beats Crispr Therapeutics on 6 of the 11 factors compared between the two stocks.

About PAREXEL International

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company’s PI segment provides information technology solutions.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

Receive News & Ratings for PAREXEL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit